Table 2 Mean cost (€) and effect differences between treatment groups and cost‐effectiveness ratios for all patients (missing data imputed).
| Effect measure | Behavioural graded activity—usual care | ||
|---|---|---|---|
| Cost difference* | Effect difference* | ICER (95% CI) | |
| QALYs (EuroQol; n = 87/92) | −1028 | −0.02 | 51385 (− 104674 to 1663872) |
| WOMAC pain (scale 0–20; n = 83/91) | −942 | 0.60 | −1575 (−103391 to 3854) |
| WOMAC physical (scale 0–68; n = 77/89) | −813 | −0.17 | 4701 (484 to 299159 |
| VAS pain now (scale 0–10; n = 84/91) | −952 | 0.27 | −3476 (−652950 to 869) |
| VAS pain past week (scale 0–10; n = 84/89) | −1016 | 0.13 | −7699 (−8101771 to −1865) |
| PGA (% improved; n = 83/87) | −1005 | 6.5 | −15462 (−4732743 to 9039)† |
| Responders OARSI criteria (%; n = 90/100) | −773 | 6.5 | −11886 (−1484690 to 697)† |
ICER, Incremental cost‐effectiveness ratio; OARSI, Osteoarthritis Research Society International; PGA, Patient Global Assessment Scale; QALY, quality‐adjusted life years; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster Universities.
*Cost and effect difference corrected for clustering within the factor physiotherapist.
†Incremental cost per patient improved/responder.